Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
X-Linked cytopenia characterized by anemia and/or thrombocytopenia. Additional features including platelet dysfunction, dyserythropoesis, mild beta-thalassemia, neutropenia, or congenital erythropoetic porphyria may be present. These GATA1 variants are germline as opposed to GATA1 variants seen in leukemia.
No HPO annotations are available for this condition.
Individuals with GATA1-related cytopenia have thrombocytopenia, anemia, and/or neutropenia.
Bleeding disorder. Males typically present in infancy with a bleeding disorder. Affected individuals have easy bruising and mucosal bleeding (e.g., gingival bleeding, epistaxis). Petechiae, ecchymoses, and/or splenomegaly may be identified on physical examination. Excessive hemorrhage and/or bruising can occur either spontaneously or after trauma or surgery. Fetal cerebral hemorrhage with in utero demise has been reported . Platelet counts are usually low (10-100 x 103/L) but can vary considerably.
GATA1-related cytopenia should be suspected in a male or female proband with any combination of the following clinical and laboratory findings and family history.
Clinical findings
Excessive bruising
Mucosal bleeding (e.g., gingival bleeding, epistaxis)
No approved treatments are currently available for GATA1-Related X-Linked Cytopenia. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with GATA1-related cytopenia, the following are recommended:
Complete blood count (CBC) and examination of the peripheral blood smear to assess the degree of cytopenia(s) and morphologic abnormalities
The frequency of CBCs should be tailored to disease severity.
Individuals with mild cytopenias should have annual CBCs.
Individuals with severe cytopenias who require transfusions should have monthly CBCs or as indicated by clinical signs and symptoms.
No clinical trials have been registered for GATA1-Related X-Linked Cytopenia.
6 publications have been identified in PubMed for GATA1-Related X-Linked Cytopenia. Research spans Gene Therapy / Novel Therapeutics (33%), Diagnostic / Biomarker (17%), and Review / Meta-Analysis (17%).
Karr M (2026). [PMID: 42037755](https://pubmed.ncbi.nlm.nih.gov/42037755/). *EJHaem*. [Review / Meta-Analysis]
Gohary AE (2026). [PMID: 42149207](https://pubmed.ncbi.nlm.nih.gov/42149207/). *Pediatr Nephrol*. [Case Report / Case Series]
Aluri S (2025). [PMID: 40424086](https://pubmed.ncbi.nlm.nih.gov/40424086/). *The Journal of clinical investigation*. [Gene Therapy / Novel Therapeutics]
Furer N (2025). [PMID: 40579545](https://pubmed.ncbi.nlm.nih.gov/40579545/). *Nature medicine*. [Diagnostic / Biomarker]
Xu H (2024). [PMID: 38961467](https://pubmed.ncbi.nlm.nih.gov/38961467/). *BMC medical genomics*. [Gene Therapy / Novel Therapeutics]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:32 PM UTC
Common questions about GATA1-Related X-Linked Cytopenia
Source: GeneReviews — "GATA1-Related Cytopenia"
Hydrops fetalis in some infants
Laboratory findings
Source: GeneReviews — "GATA1-Related Cytopenia"
GATA1-related cytopenia must be distinguished from other acquired and hereditary thrombocytopenias (e.g., Wiskott-Aldrich syndrome, which is also X-linked), platelet function abnormalities, and anemias . Algorithms exist to help differentiate among these disorders . However, the clinical phenotypes of GATA1-related cytopenias vary greatly and overlap considerably with other genetic causes of cytopenia. Hence, a genetic diagnosis is almost always required for confirmation. A multigene panel is often used to establish the diagnosis of a hereditary thrombocytopenia and thereby facilitate appropriate surveillance (some types of hereditary thrombocytopenia are associated with increased malignancy risk) and genetic counseling. Of note: • Numerous congenital thrombocytopenias may be considered in the differential diagnosis . In GATA1-related thrombocytopenia, platelets are usually large and may be hypogranular. There may be associated platelet aggregation defects and/or a prolonged bleeding time. Relatively common congenital causes of macrothrombocytopenia that could be confused with GATA1-related disorders are described in . • Thrombocytopenia may be the initial manifestation of bone marrow failure in individuals with a telomere biology disorder (e.g., dyskeratosis congenita). • Cryptorchidism and/or hypospadias may suggest the involvement of GATA1 but are not always present. • Congenital causes of anemia that could potentially be confused with GATA1-related disorders are described in . Table 3. Selected Genes of Interest in the Differential Diagnosis of GATA1-Related Cytopenia
Gene | Disorder | MOI | Clinical Characteristics |
|---|---|---|---|
ETV6 thrombocytopenia predisposition to leukemia | AD | Mild-to-moderate thrombocytopenia w/platelet function defects; risk of hematologic malignancy RUNX1 | — |
RUNX1 familial platelet disorder w/assoc myeloid malignancies | AD | Mild-to-moderate thrombocytopenia w/platelet function defects; risk of hematologic malignancy | — |
WAS | Wiskott-Aldrich syndrome (See WAS-Related Disorders.) | XL | Small platelets, eczema (~80%), immunodeficiency; persons may have isolated microthrombocytopenia. Congenital macrothrombocytopenia GP1BA GP1BB |
GP9 | Bernard-Soulier syndrome (BSS) (OMIM 231200) | AR | Severe bleeding disorder w/severely defective ristocetin-induced platelet agglutination; heterozygotes may have mild disease. GP1BA |
GP1BB | Mediterranean thrombocytopenia (OMIM 153670) | AD | Phenotype typically milder than BSS; dysmegakaryo-cytopoiesis2 MYH9 |
MYH9-related disease | AD | Platelet macrocytosis, thrombocytopenia, neutrophil inclusions; most persons have extrahematologic manifestation(s) (e.g., hearing loss, cataract, renal defects). | — |
NBEAL22 | Gray platelet syndrome (OMIM 139090) | AR3 | Pale platelets /or absent alpha granules. Anemia BRCA1 BRCA2 BRIP1 ERCC4 FA... |
Source: GeneReviews — "GATA1-Related Cytopenia"
Biomarker and diagnostic research for GATA1-Related X-Linked Cytopenia has been reported in the published literature.
Detailed history of the disease course, including the age at which hematologic disease was detected and the associated symptoms
Documentation of abnormal/unexpected bleeding episodes and platelet counts obtained at the time of the episodes to help determine whether platelet function is abnormal and whether disease severity has changed over time
Note: Platelet aggregation studies may identify functional abnormalities that predict a greater risk of bleeding for any given platelet count, but studies can be difficult to interpret when platelet counts are lower than 100,000/L.
Consultation with a medical geneticist, certified genetic counselor, or certified advanced genetic nurse to inform affected individuals and their families about the nature, mode of inheritance, and implications of GATA1-related cytopenia for medical and personal decision making
Treatment of Manifestations
Targeted Therapy
Source: GeneReviews — "GATA1-Related Cytopenia"
Individuals with thrombocytopenia and/or platelet aggregation defects should avoid antiplatelet agents including aspirin and nonsteroidal anti-inflammatory drugs (e.g., ibuprofen). Individuals with thrombocytopenia and/or platelet aggregation defects should avoid contact sports or activities with a high risk of trauma. Individuals with severe neutropenia should avoid close contact with persons who have a communicable disease to minimize risk of infection. Individuals with significant splenomegaly should avoid contact sports, which increase the risk of traumatic splenic rupture.
Source: GeneReviews — "GATA1-Related Cytopenia"
Correction of the GATA1 pathogenic variant by genome editing of autologous hematopoietic stem cells may offer a viable cure in the future, although this will require individualized "n-of-few" therapy since there is no single common pathogenic variant . Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "GATA1-Related Cytopenia"
View trials for GATA1-Related X-Linked Cytopenia
Individuals undergoing repeated erythrocyte transfusions should be monitored for iron overload.
Source: GeneReviews — "GATA1-Related Cytopenia"